The combination of Keytruda and Padcev is taking another major step toward securing its position as a leading therapy in the ...
“PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of ...
A diagnosis of adenocarcinoma of the bladder requires careful and specialized care. Because it is rare, it is essential to be treated by a multidisciplinary team, including a urologic oncologist, ...
Merck says Keytruda plus Padcev improved survival and response rates versus chemotherapy in a Phase 3 muscle-invasive bladder ...
Pfizer and Astellas now have two studies supporting the use of Padcev with MSD's Keytruda as a perioperative therapy for ...
Armed with new three-year data demonstrating the benefits of Anktiva in a specific patient subset, ImmunityBio is proving its bladder cancer med is still one to watch as it competes with heavy hitt | ...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive topline results from an interim analysis of the Phase 3 EV-304 ...
MSK also combines these treatments, depending on whether the tumor has grown into the muscle or metastasized (spread). Our goal is to preserve your bladder or rebuild it, if removing it was the best ...
In the last couple of years, Professor Syed Hussain has become increasingly concerned by the growing number of patients presenting with bladder cancer at an advanced stage. “Since Covid, there has ...
A groundbreaking study introduces new noninvasive screening tools that have the potential to greatly enhance patient comfort ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results